Apatinib, a small-molecule VEGFR-tyrosine kinase inhibitor, selectively acts on the intracellular ATP binding site of VEGFR-2, which plays a central role in the regulation of angiogenesis.14 It blocks VEGF-VEGFR downstream signal transduction, leading to tumor angiogenesis inhibition. Here, KDR is linked to neoplasm.